PayerTalkCE Presents: Understanding Type 2 Inflammation: Spotlight on Eosinophilic Esophagitis

Track 1 - Understanding T2 Inflammation: Spotlight on Eosinophilic Esophagitis
Track 2 - Understanding T2 Inflammation: Best Practices in EoE Management

Learn About:

1. Payer care management initiatives and other opportunities to improve treatment access and overall quality of care
2. How T2 inflammation plays a central role in EoE pathophysiology
3. The safety and efficacy of evolving treatments

Expert Faculty Presenters:

Dana McCormick, RPh, FAMCP Senior Director, Pharmacy Advisory Services Optum Insights Click here for biography Evan S. Dellon, MD, MPH Professor of Medicine and Adjunct Professor of Epidemiology University of North Carolina School of Medicine Click here for biography Drake Reiter, PharmD Director, Pharmacy Operations Priority Health Click here for biography

Target Audience
This activity is designed to meet the educational needs of managed care pharmacy directors, registered nurses, clinical pharmacists, quality directors and medical directors.

Statement of Need/Program Overview
Managed care professionals report having limited knowledge of EoE pathology, noting that misdiagnosis and underdiagnosis are common issues preventing patients from receiving timely and accurate treatment. In conditions like EoE, where understanding of the disease mechanisms is still developing, managed care payers may not prioritize these conditions highly. Therefore, managed care professionals must understand the disease, treatment protocols, and evidence-based practices to identify effective, safe, and cost-efficient medications for their formularies. A deeper understanding of T2 inflammation will enable these professionals to collaborate more effectively with specialist physicians, ensuring that care plans are comprehensive, aligned with clinical guidelines, and free from unnecessary administrative barriers to appropriate care.

Educational Objectives
After completing this activity, the participant should be better able to:

• Describe how T2 inflammation plays a central role in EoE pathophysiology
• Summarize safety and efficacy of treatments for patients with EoE
• Assess payer care management initiatives and other opportunities to improve treatment access and overall quality of care based on current evidence from clinical trials and treatment guidelines

Accreditation Information

Joint Accreditation Statement In support of improving patient care, this activity has been planned and implemented by Partners for Advancing Clinical Education (PACE) and Impact Education, LLC. PACE is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education
PACE designates this live activity for a maximum of 2.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Continuing Pharmacy Education
PACE designates this continuing education activity for 2.0 contact hours (0.20 CEUs) of the Accreditation Council for Pharmacy Education.

Track 1
UAN: JA4008073-9999-24-220-L01-P
Type of Activity: Application

Track 2
UAN: JA4008073-9999-24-221-L01-P
Type of Activity: Application

Continuing Nursing Education
The maximum number of hours awarded for this Continuing Nursing Education activity is 2.0 contact hours.

Disclosure of Conflicts of Interest
PACE requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial relationships they may have with ineligible companies. All relevant financial relationships are thoroughly vetted and mitigated according to PACE policy. PACE is committed to providing learners with high-quality accredited CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships with ineligible entities related to the educational content of this CE activity:

DISCLOSURE OF UNLABELED USE
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

DISCLAIMER
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

FEE INFORMATION
There is no fee for this educational activity.